Cellyan Biotechnology Co., Ltd (HKPD) is a Hong Kong–based healthcare logistics and distribution business centered on over-the-counter (OTC) pharmaceutical products for customers operating across Hong Kong and mainland China. The company functions as an investment holding entity and positions its core offering around international sourcing and distribution of OTC medications, ...Cellyan Biotechnology Co., Ltd (HKPD) is a Hong Kong–based healthcare logistics and distribution business centered on over-the-counter (OTC) pharmaceutical products for customers operating across Hong Kong and mainland China. The company functions as an investment holding entity and positions its core offering around international sourcing and distribution of OTC medications, paired with end-to-end e-commerce supply chain capabilities.
From a business perspective, HKPD serves ecosystem participants such as logistics partners for e-commerce platforms, merchants, and pharmaceutical distributors. Rather than only acting as a traditional wholesaler, the company emphasizes operational services that remove friction from cross-border fulfillment—customs clearance and regulatory-oriented support (including drug registration), plus warehousing and logistics execution. This model typically depends on maintaining reliable supplier relationships for OTC product sourcing, compliance processes for import/registration, and fast fulfillment performance supported by inventory/warehouse management.
In terms of products and services, HKPD’s revenue is generally driven by procurement-and-distribution activities and by service components that may include handling, storage, customs-related processing, and related supply-chain management for cross-border e-commerce transactions. Cost and BOM (bill of materials) in this context commonly involve product procurement costs (including landed costs), warehousing/handling expenses, freight and last-mile logistics, customs clearance charges, and compliance/registration-related costs. Operating efficiency is therefore closely linked to inventory turnover, receivables/payables cycles, and warehouse utilization.
Financially, the provided TTM snapshot indicates profitability pressure: margins are negative (e.g., net profit margin and operating profit margin are both approximately -8.5% and -7.4% respectively), and returns on assets and equity are also negative (ROA around -11.8% and ROE around -22.4%). The company also shows a cash-conversion-cycle profile that reflects working-capital intensity (DSO notably high in the provided metrics), which can impact near-term liquidity and funding requirements—especially important for a logistics/distribution business that must finance inventory and receivables.
Key people include CEO and Director Chenyu Liang (listed in the referenced filing). The company has undergone branding evolution: it was formerly known as Hong Kong Pharma Digital Technology Holdings Limited and adopted the name Cellyan Biotechnology Co., Ltd in December 2025. Founded/incorporated in 2023, the company reported a small team size (employees in the tens), consistent with a lean operating structure for an early-growth distribution and logistics platform.
Overall, HKPD’s outlook hinges on scaling cross-border OTC demand while improving unit economics—particularly by optimizing logistics throughput, reducing working-capital strain, and converting operating volume into sustainable gross and operating profits. The company has also indicated planned use of capital raised for business expansion, working capital, and general corporate purposes, aligning with its operational growth needs.
